Product Description: Fevipiprant (QAW039, NVP-QAW039) is s an orally active, selective, reversible prostaglandin D2 (DP2) receptor antagonist with an Kd value of 1.14 nM. Fevipiprant has the potential for the research of bronchial asthma[1][2][3].
Applications: Cancer-programmed cell death
Formula: C19H17F3N2O4S
References: [1]Brightling C, et al. The pharmacology of the prostaglandin D2 receptor 2 (DP2) receptor antagonist, fevipiprant. Pulm Pharmacol Ther. 2021 Jun;68:102030./[2]Lee HY, et al. Blockade of thymic stromal lymphopoietin and CRTH2 attenuates airway inflammation in a murine model of allergic asthma. Korean J Intern Med. 2020 May;35(3):619-629. /[3]Weintraub NL, et al. Role of prostaglandin D2 receptors in the pathogenesis of abdominal aortic aneurysm formation. Clin Sci (Lond). 2022 Mar 18;136(5):309-321.
CAS Number: 872365-14-5
Molecular Weight: 426.41
Compound Purity: 99.63
Research Area: Cardiovascular Disease
Solubility: DMSO : ≥ 32 mg/mL
Target: CRTH2 (GPR44);Prostaglandin Receptor
Deutsch
English
